Mirae Asset Global Etfs Holdings Ltd. Moon Lake Immunotherapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 16,730 shares of MLTX stock, worth $909,108. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,730Holding current value
$909,108% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
127Shares Held
58MCall Options Held
103KPut Options Held
79.7K-
Bvf Inc San Francisco, CA21.8MShares$1.18 Billion29.25% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$462 Million28.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$151 Million1.66% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.56MShares$139 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.27MShares$123 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.01B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...